Hypertension

CENTER VALLEY, Pa., March 19, 2024 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today it applauds the new Obesity Bill of Rights . Continue Reading Olympus applauds the newly launched Obesity Bill of Rights and will support the initiative by working to build awareness and talking to its healthcare customers about this important campaign to counter bias and ageism in obesity care. Olympus will support the initiative by working to build awareness and talking to its healthcare customers about this important campaign to counter bias and ageism in obesity care. The program, spearheaded in January 2024 in the U.S. by the National Consumers League (NCL), a nonprofit consumer advocacy group, in conjunction with the National Council on Aging (NCOA), establishes a set of rights to "assure screening, diagnosis, counseling and effective treatment based on medical treatment guidelines." This ongoing effort to gather support is expected to culminate in a fully implemented Bill of Rights by Dec. 31, 2029. The NCL and NCOA are working at the grassroots, employer, state and federal levels on this effort to ensure equal access to care for all obesity patients. NCL and NCOA worked with health leaders and obesity specialists to draft these Bill of Rights tenets that are intended to change the narrative, such that the healthcare industry more effectively sees obesity as a treatable chronic disease that can be treated with the same "respect, attention and medical care" as other chronic conditions. Statistics regarding obesity are staggering: 108M people in the U.S. are considered obese, only 10% of whom get help from medical professionals and only 2% of whom are treated with new medications. More than 230 conditions are worsened by obesity. Obesity is connected to $1.73 trillion in annual medical costs in the U.S. 400K premature deaths annually are linked to obesity.1 "Olympus provides equipment to the surgical community that helps in the treatment of obesity, and statistics show that not enough people have access to this type of treatment," said Paul Skodny, Executive Director for Health Economics and Market Access at Olympus Corporation. "It is our hope that awareness of treatment options and equitable access and insurance coverage will help address the detrimental health impacts of obesity." Bariatric Surgery as a Solution for Weight Loss Because of recent pharmaceuticals' entry into the market, such as semaglutide-based medications, obesity treatment has been receiving more attention. Surgical treatment which can complement medical management, has a lengthy track record, having been available to patients for decades with favorable long-term outcomes.2 Studies show patients typically lose the most weight one to two years after bariatric surgery and see substantial improvements in obesity-related conditions. Despite the growing number of obesity-related health problems, fewer than 2% of those eligible for bariatric surgery elect to have it.3 Given these statistics, Olympus, maker of technologies for performing minimally invasive bariatric procedures, sought to understand the awareness level and concerns of eligible patients in a survey conducted in 20194: Marginal Awareness around Benefits: A little more than 50% of respondents demonstrated only marginal awareness that bariatric surgery causes hormonal changes that improve weight loss by maintaining or enhancing energy expenditure.5 Worry about Gaining Weight Back: 20% of respondents were avoiding bariatric surgery because of concerns about surgery complications and gaining the weight back. Awareness around Insurance Opportunities: 56% of respondents were aware that insurance covers bariatric surgery in most qualified cases.6 Surgical benefits are real and should be known to more patients. Studies show that: Patients may lose as much as 60% of excess weight six months after surgery, and 77% of excess weight as early as 12 months after surgery. On average, five years after surgery, patients maintain 50% of their excess weight loss.1 The majority of bariatric surgery patients with diabetes, dyslipidemia, hypertension, and obstructive sleep apnea experience remission of these obesity-related diseases.1 Statistically, the risk of death during weight-loss surgery procedures is less than 1 percent. All abdominal operations carry the risks of bleeding, infection in the incision, thrombophlebitis of legs (blood clots), lung problems (pneumonia, pulmonary embolisms), strokes or heart attacks, anesthetic complications and blockage or obstruction of the intestine. These risks are greater in patients with severe obesity.7 To learn more about Olympus' state-of-the-art technologies for performing minimally invasive bariatric surgeries, visit the Bariatrics product page. About Olympus At Olympus, we are committed to our purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals striving to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit medical.olympusamerica.com. _______________________________ 1 Americans now have an Obesity Bill of Rights. NCLnet.org. . Published January 31, 2024. Accessed February 29, 2024. 2 Story of Obesity Surgery. asmbs.org. . Published 2023. Accessed February 29, 2024. 3 . February 27, 2020. Accessed February 29, 2024. 4 The Olympus-commissioned online survey was conducted mid-December 2019. 5 Public Education Committee. Benefits of Bariatric Surgery: ASMBS. American Society for Metabolic and Bariatric Surgery. . Accessed February 29, 2024. 6 Manning S. How to get your health insurer to pay for your weight-loss surgery. Insure.com. . Published September 24, 2020. Accessed February 29, 2024. 7 Available Procedures. Yale New Haven Health. . Accessed March 15, 2024. SOURCE Olympus Corporation of the Americas

Lubbock–area surgery center remains one of only two dozen in the country to meet all criteria to achieve accreditation from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program®, demonstrating the highest standards for patient safety and quality LUBBOCK, Texas, March 19, 2024 /PRNewswire/ -- Covenant High Plains Surgery Center announced today that its ambulatory surgery center (ASC) has been reaccredited by the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP®), a joint Quality Program of the American College of Surgeons (ACS) and the American Society for Metabolic and Bariatric Surgery (ASMBS). MBSAQIP Accreditation is normally the domain of hospital programs, and fewer than two dozen surgery centers in the nation have merited this designation. Dr. Adam Purtell, Metabolic and Bariatric Surgery Director at Covenant High Plains Surgery Center (CHPSC), made the announcement, noting that West Texas and Eastern New Mexico patients seeking outpatient, surgical treatment for obesity and its related conditions will continue to have a high-quality, cost-effective choice for receiving care at a nationally accredited program that meets the highest standards for patient safety and quality. The MBSAQIP Standards, Optimal Resources for Metabolic and Bariatric Surgery, ensure that metabolic and bariatric patients receive multidisciplinary medical care, which improves patient outcomes and long-term success. MBSAQIP-accredited surgery centers offer preoperative and postoperative care designed specifically for patients with obesity. "We are excited about the opportunity to continue to offer Lubbock and the West Texas community an excellent Bariatric surgery experience in the only MBSAQIP-accredited ambulatory surgery center in the region," said Dr. Purtell. "Our fellowship-trained Bariatric surgeons provide tremendous quality and outcomes at affordable cost. The accreditation also allows many insured patients with bariatric benefits the opportunity to change their lives as well, with long term weight loss and improvement of medical conditions." CHPSC's commitment to quality care begins with its expertly trained staff and the leadership of an experienced bariatric surgeon. The program is tasked with continuous review of surgical data as they continue improving the structure and outcomes expertise necessary to provide safe, efficacious, and high-quality care to all metabolic and bariatric patients. To earn MBSAQIP Accreditation, CHPSC met essential criteria for staffing, training, facility infrastructure and patient care pathways, ensuring its ability to support patients with obesity. The center also participates in a national data registry that yields semiannual reports on the quality of its surgical outcomes and identifying opportunities for quality improvement. The MBSAQIP Standards, Optimal Resources for Metabolic and Bariatric Surgery, are published by the ACS and the ASMBS. After applying for MBSAQIP accreditation, centers undergo an extensive site visit by an experienced bariatric surgeon who reviews the center's structure, processes, and clinical outcomes data. Centers that earn accreditation are awarded a specific designation level, depending on how many patients it serves annually, critical care capabilities, the types of procedures provided, and whether it provides care to patients under the age of 18. The Centers for Disease Control and Prevention (CDC) estimates about 93 million adults in the United States are affected by obesity and that number continues to increase. The disease of obesity increases the risks of morbidity and mortality because of the diseases and conditions that are commonly associated with it, such as type II diabetes, hypertension, cardiovascular disease, and cancer, among other health risks. Metabolic and bariatric surgery has proven to be effective in the reduction of comorbid conditions related to obesity.* Working together, the ACS and the ASMBS have developed accreditation standards for metabolic and bariatric surgery to assist patients with obesity in identifying centers that provide optimal patient care. "We are proud to provide this level of care in an ambulatory surgery setting to patients in West Texas," stated CHPSC Administrator Alfonso del Granado, a bariatric patient himself who supports his organization's dedication to excellence. "Too many patients are not able to afford the treatment options available at large hospital programs or have to compromise by seeking care at non-accredited centers. With this reaccreditation, we are demonstrating our commitment to offer patients the highest standards of care." About Covenant High Plains Surgery Center, LLC Covenant High Plains Surgery Center (CHPSC) operates two freestanding, independent multispecialty ambulatory surgery centers (ASCs) in Lubbock, Texas with joint-venture partners Covenant Health System and National Cardiovascular Partners (NCP). Fully accredited by the Accreditation Association for Ambulatory Health Care and the American Society for Metabolic and Bariatric Surgery, CHPSC runs 14 operating and procedure rooms with more than a hundred physicians on staff. CHPSC features robotic general surgery, urology, and total joint replacement programs, as well as advanced surgical treatment options in bariatrics, ENT, general surgery, GI, gynecology, interventional pain, neuro & spine surgery, ophthalmology, orthopedics, maxillofacial, plastic & reconstructive surgery, podiatry, and urology to patients from Texas, New Mexico, and Oklahoma. For more information, visit . About the American College of Surgeons The American College of Surgeons (ACS) is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical education and practice and to improve the quality of care for surgical patients. Its achievements have placed it at the forefront of American surgery and have made the College an important advocate for all surgical patients. The College has more than 82,000 members and is the largest organization of surgeons in the world. About the American Society for Metabolic and Bariatric Surgery The American Society for Metabolic and Bariatric Surgery (ASMBS) is the largest organization for metabolic and bariatric surgeons in the world, with more than 4,200 members. It is a not-for-profit organization that works to advance the science of metabolic and bariatric surgery. The ASMBS is committed to educating medical professionals and the lay public about metabolic and bariatric surgery, including the associated risks and benefits, as a treatment option for obesity. *Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery: A Systematic Review and Meta-analysis. JAMA. 2004;292(14):1724-1737. DOI:10.1001/jama.292.14.1724. SOURCE Covenant High Plains Surgery Center

Pictured: Blood sample for insulin-like growth factor-1 (IGF-1)/iStock, Jarun011 Crinetics Pharmaceuticals has secured another late-stage win as its oral, once-daily investigational drug paltusotine aced a second Phase III study for acromegaly, a rare hormonal disorder. The biotech’s stock shot up over 10% Tuesday morning following the announcement. In the late-stage trial, 56% of patients taking paltusotine achieved the primary endpoint for the insulin-like growth factor 1 (IGF-1) level compared to 5% on placebo. The treatment also helped reduce symptoms of the disease—a secondary endpoint of the study. No serious adverse events were reported. Acromegaly, sometimes referred to as gigantism, is a serious hormonal disorder caused by a benign tumor in the pituitary gland that secretes growth hormone. Over 25,000 patients in the U.S. suffer from the rare disease, which results in enlargement of face, hands and feet. Left untreated, it can cause type 2 diabetes, hypertension, heart disease and other serious complications. Surgical removal of the tumor is the preferred treatment but many patients are not candidates for surgery. Current pharmacological options include painful monthly injections or Pfizer’s subcutaneous daily injection of Somavert. The Phase III data are the second positive trial results for Crinetics in acromegaly. In September 2023, the biotech shared data for a study of paltusotine in patients who switched from their current injections to Crinetics’ pill. Among treated patients, 83% were able to maintain their IGF-1 levels within the upper limit of normal, compared to only 4% of those on placebo. With these data in hand, Crinetics plans to submit its New Drug Application to the FDA in the second half of this year, while prepping for a 2025 launch. Jefferies analysts believe the market opportunity could be around $300 million for the company. Crinetics is also testing the drug candidate in carcinoid syndrome, reporting positive Phase II topline results last week. Kate Goodwin is a freelance life science writer based in Des Moines, Iowa. She can be reached at kate.goodwin@biospace.com and on LinkedIn.